SCHEMBL1979321

SCHEMBL1979321

NC(=O)C1CCC=CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28033016 0.98 GLI1 (0.35)
SCHEMBL325433 0.80
SCHEMBL15330716 0.80
SCHEMBL931733 0.78
Hydrochloric Acid SCHEMBL1703549 0.78 CYP2D6 (0.37)
SCHEMBL15149517 0.77
Hydrochloric Acid SCHEMBL30530744 0.76
SCHEMBL3642481 0.74 MAPT (0.34)
SCHEMBL7218636 0.74 USP2 (0.30)
Hydrochloric Acid SCHEMBL8733450 0.72 MAPT (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1146790-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2004-03-17 EP claimed
JP-2002535256-A 2002-10-22 JP claimed
EP-1146790-A1 COMPOUNDS AND METHODS SmithKline Beecham Corporation (US) 2001-10-24 EP claimed
WO-2000042852-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2000-07-27 WO claimed
US-20250171414-A1 COMPOUND SERVING AS MASP-2 INHIBITOR, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF WUHAN CREATERNA SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2025-05-29 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed
CN-109715630-A β -lactamase inhibitor compounds 恩塔西斯治疗有限公司 2019-05-03 CN disclosed
CN-104364254-B Heterobicyclic compounds as beta-lactamase inhibitors 恩塔西斯治疗有限公司 2017-02-22 CN disclosed
EP-2844642-A1 COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS ARIAD PHARMACEUTICALS, INC. (US) 2015-03-11 EP disclosed
EP-2834239-A1 HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS Astrazeneca AB (SE) 2015-02-11 EP disclosed
WO-2013169401-A1 COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS ARIAD PHARMACEUTICALS, INC. (US) 2013-11-14 WO disclosed
WO-2013150296-A1 HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS ASTRAZENECA AB (SE) 2013-10-10 WO disclosed
CN-101801953-A Tetrahydropyridyl carboxamide derivatives as TRPV1 antagonists ABBOTT LAB 2010-08-11 CN disclosed
CN-101801953-A Tetrahydropyridyl carboxamide derivatives as TRPV1 antagonists ABBOTT LAB 2010-08-11 CN disclosed
WO-2010007382-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) 2010-01-21 WO disclosed
EP-2091936-A1 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN Purdue Pharma LP (US) 2009-08-26 EP disclosed
WO-2008133973-A1 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN PURDUE PHARMA L.P. (DE) 2008-11-06 WO disclosed
EP-1622911-A2 PYRROLO[1,2-B]PYRIDAZINE COMPOUNDS AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS Pharmacia & Upjohn Company LLC (US) 2006-02-08 EP disclosed
WO-2004099213-A2 PYRROLO (1,2-B) PYRIDAZINE COMPOUNDS AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS PHARMACIA & UPJOHN COMPANY LLC (US) 2004-11-18 WO disclosed
US-5525600-A COMPOUND USEFUL AS ANTIPSYCHOTIC, ANTIDEPRESSANT AND ANXIBLYTIC AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1996-06-11 US disclosed